Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. News
  7. Summary
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Morgan Stanley Downgrades AVROBIO to Equal-Weight From Overweight, Adjusts Price Target to $7 From $24

11/19/2021 | 09:07am EST


© MT Newswires 2021
All news about AVROBIO, INC.
01/07AVROBIO Gets Approval to Cut 23% of Workforce
MT
01/07AVROBIO : Current Report (Form 8-K)
PU
01/07AVROBIO, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or ..
AQ
01/06Mizuho Adjusts AVROBIO's Price Target to $6 from $28, Keeps Buy Rating
MT
01/06AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/06NORTH AMERICAN MORNING BRIEFING : Tech Stocks Set -3-
DJ
01/05Morgan Stanley Adjusts Price Target on AVROBIO to $3 From $7, Maintains Equal-Weight Ra..
MT
01/05Needham Adjusts AVROBIO's Price Target to $8 From $28, Reiterates Buy Rating
MT
01/05BTIG Downgrades AVROBIO to Neutral From Buy
MT
01/05Barclays Adjusts AVROBIO's Price Target to $6 From $22, Reiterates Overweight Rating
MT
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -124 M - -
Net cash 2021 162 M - -
P/E ratio 2021 -0,65x
Yield 2021 -
Capitalization 83,4 M 83,4 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 121
Free-Float -
Chart AVROBIO, INC.
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 1,86 $
Average target price 7,00 $
Spread / Average Target 276%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-51.69%81
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-7.49%51 604
BIONTECH SE-41.44%36 465